Characteristic resistance mechanism of mycobacterium tuberculosis to DC-159a, a new respiratory quinolone

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3958-3960

  Sekiguchi, Jun Ichiro ^a   Disratthakit, Areeya ^a   Maeda, Shinji ^a   Doi, Norio ^a  

^a RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DC 159A; DNA TOPOISOMERASE (ATP HYDROLYSING); LEVOFLOXACIN; QUINOLONE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; GENE MUTATION; GENOTYPE; GYRA BACTERIAL GENE; HUMAN; IC 50; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

AMINOPYRIDINES; ANTITUBERCULAR AGENTS; DNA GYRASE; DNA, SUPERHELICAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79960330193     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00417-10     Document Type: Article

References (19)

1. Bozeman, L., W. Burman, B. Metchock, L. Welch, and M. Weiner. 2005. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin. Infect. Dis. 40:386-391.
2. Cheng, A. F., et al. 2004. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 48:596-601. (Pubitemid 38141721)
3. Disratthakit, A., and N. Doi. 2010. In vitro activities of DC-159a, a novel fluoroquinolone against Mycobacterium species. Antimicrob. Agents Chemother. 54:2684-2686.
4. Doi, N., A. Disratthakit, S. Ogiso, S. Uoyama, and Y. Kurosaka. 2006. In vivo efficacy of DC-159a, a new generation of respiratory quinolone, against experimental murine tuberculosis due to multi-drug-resistant Mycobacterium tuberculosis, abstr. F1-0492. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
5. Hooper, D. C. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7:337-341.
6. Maeda, S., Y. Y. Murase, S. Mitarai, I. I. Sugawara, and S. Kato. 2008. Rapid, simple genotyping method by the variable numbers of tandem repeats (VNTR) for Mycobacterium tuberculosis isolates in Japan - analytical procedure of JATA (12)-VNTR. Kekkaku 83:673-678. (In Japanese.)
7. Marcusson, L. L., N. Frimodt-Møller, and D. Hughes. 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog. 5:e1000541. doi:10.1371/journal.ppat.1000541.
8. Matrat, S., et al. 2006. Functional analysis of DNA gyrase mutant enzymes carrying mutation at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob. Agents Chemother. 50:4170-4173. (Pubitemid 44865162)
9. New England Biolabs. 2006. Impact-CN instruction manual. New England Biolabs, Ipswich, MA. http://www.neb.com/nebecomm/ManualFiles/manualE6900.pdf.
10. Onodera, Y., M. Tanaka, and K. Sato. 2001. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 47:447-450. (Pubitemid 32303411)
11. Onodera, Y., T. Hirata, K. Hoshino, and T. Otani. 2007. DC-159a, a novel quinolone, showed high inhibitory activity against altered topoisomerases of Streptococcus pneumoniae and Mycobacterium tuberculosis, abstr. F1-2126. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., American Society for Microbiology, Washington, DC.
12. Pitaksajjakul, P., et al. 2005. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J. Trop. Med. Public Health 36(Suppl. 4):228-237.
13. Rodríguez, J. C., et al. 2004. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J. Antimicrob. Chemother. 53:441-444. (Pubitemid 38380240)
14. Rozen, D. E., L. McGee, B. R. Levin, and K. P. Klugman. 2007. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:412-416.
15. Siddiqi, N., et al. 2002. Molecular characterization of multi-drug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob. Agents Chemother. 46:443-450.
16. van Embden, J. D., et al. 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J. Clin. Microbiol. 31:406-409.
17. Von Groll, A., et al. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500.
18. Working group on new TB drugs. 2010. New respiratory quinolone DC-159a. Working group on new TB drugs. http://www.newtbdrugs.org/project.php?id=134.
19. Zhang, Y., and A. Telenti. 2000. Genetics of drug resistance in Mycobacterium tuberculosis, p. 235-254. In G. F. Hatfull and W. R. Jacobs (ed.), Molecular genetics of mycobacteria. American Society for Microbiology, Washington, DC.